Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain 3Malignant Female Reproductive System Neoplasm 2Rectal Neoplasms 1Pulmonary Nodule 1Pain, Postoperative 1Neoplasms 1Ileus 1Hematologic Neoplasms 1Emergencies 1Diverticulosis, Colonic 1Diverticulitis, Colonic 1Constipation 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Agnosia 1

Interventions

ceftolozane, tazobactam drug combination 2Meropenem 2Itraconazole 2rasburicase 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1fludarabine phosphate 1fludarabine 1eltrombopag 1drotrecogin alfa activated 1dexamethasone 21-phosphate 1Voriconazole 1Vancomycin 1Uric Acid 1Urate Oxidase 1Tropisetron 1Teicoplanin 1Solutions 1Ribavirin 1Pegloticase 1Oxidoreductases 1Ofloxacin 1Micafungin 1Metronidazole 1Imatinib Mesylate 1Hydromorphone 1Human Papillomavirus Recombinant Vaccine nonavalent 1Dexamethasone 1Dasatinib 1Ciprofloxacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Hematologic Neoplasms × Hydromorphone × Clear all
NCT04296305 2025-12-26

Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

M.D. Anderson Cancer Center

Phase 4 Active not recruiting
84 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡